NASDAQ:GILDGilead Sciences Stock Price, Forecast & News

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GILD stock has increased by 3.6% and is now trading at $76.35. View which stocks have been most impacted by Coronavirus.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 3 sell ratings, 15 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Gilead Sciences.

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gilead Sciences.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.57 by $0.11. The biopharmaceutical company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The company's revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.67 earnings per share. View Gilead Sciences' earnings history.

Gilead Sciences declared a quarterly dividend on Thursday, April 30th. Shareholders of record on Friday, June 12th will be paid a dividend of $0.68 per share on Monday, June 29th. This represents a $2.72 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date of this dividend is Thursday, June 11th. View Gilead Sciences' dividend history.

28 Wall Street analysts have issued twelve-month price targets for Gilead Sciences' stock. Their forecasts range from $60.00 to $97.00. On average, they expect Gilead Sciences' stock price to reach $79.65 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price. View analysts' price targets for Gilead Sciences.

Media coverage about GILD stock has trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gilead Sciences earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Gilead Sciences.

Gilead Sciences saw a decline in short interest in June. As of June 15th, there was short interest totaling 24,140,000 shares, a decline of 7.5% from the May 31st total of 26,090,000 shares. Based on an average daily volume of 21,470,000 shares, the days-to-cover ratio is presently 1.1 days. Currently, 1.9% of the company's stock are short sold. View Gilead Sciences' Current Options Chain.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Intel (INTC), Micron Technology (MU), AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T) and Tesla (tsla).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Confluence Investment Management LLC (0.10%), Thomasville National Bank (0.01%), First Financial Bank Trust Division (0.01%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%) and Modus Advisors LLC (0.00%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View institutional ownership trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, and Olsen Per Wold. View insider buying and selling activity for Gilead Sciences.

GILD stock was bought by a variety of institutional investors in the last quarter, including Thomasville National Bank, First Financial Bank Trust Division, and Modus Advisors LLC. View insider buying and selling activity for Gilead Sciences.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GILD stock can currently be purchased for approximately $76.35.

Gilead Sciences has a market capitalization of $95.77 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

The official website for Gilead Sciences is www.gilead.com.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]